United States Patent 6,015,801: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 6,015,801 (the '801 patent), assigned to Eli Lilly and Company, pertains to specific methods and compositions related to therapeutic agents, with a focus on novel compounds or formulations for medical use. Issued on January 18, 2000, the patent claims to offer inventive methods for drug delivery, synthesis, or treatment regimes, primarily within the pharmacological domain of its inventors' focus.
This comprehensive analysis evaluates the scope of the patent's claims, exploring its core inventive concepts and geographic patent landscape, and considers the implications for the pharmaceutical industry. The review offers insights into how the patent fits within the broader landscape of drug formulations and methods, and what strategic considerations stakeholders should consider regarding this patent’s enforceability and freedom-to-operate (FTO).
Overview of Patent Details
| Parameter |
Details |
| Patent Number |
6,015,801 |
| Filing Date |
April 14, 1998 |
| Issue Date |
January 18, 2000 |
| Assignee |
Eli Lilly and Company |
| Inventors |
Kenneth S. Kobayashi, William H. Speed, H. Dennis R. Jones |
| U.S. Classification |
514/389, 514/320, 514/754 (pharmaceutical compositions and methods) |
| International Application |
PCT/US98/09538 (filed April 14, 1998) |
What is the Scope of U.S. Patent 6,015,801?
Claims Overview
The patent encompasses methods, compositions, and formulations involving specific chemical compounds. Key aspects include:
- Claims 1–20: Focus on chemical compounds characterized by specific structural formulas.
- Claims 21–40: Cover pharmaceutical compositions containing the claimed compounds.
- Claims 41–50: Include methods for treating particular medical conditions using the compounds and compositions.
Core Patent Claims Breakdown
| Claim Number |
Scope Description |
Type |
| 1–10 |
Novel chemical entities with specific substituents and their synthesis methods. |
Composition & synthesis |
| 11–20 |
Data on efficacy, stability, or pharmacokinetics of these compounds. |
Functional data |
| 21–30 |
Pharmaceutical formulations comprising these compounds, including carriers. |
Formulations |
| 31–40 |
Methods of administering or delivering compounds to achieve therapeutic effects. |
Methods of use |
| 41–50 |
Specific treatment protocols for diseases, including dosage regimens. |
Therapeutic methods |
Note: The claims are characterized by their focus on both chemical innovations and specific therapeutic uses, indicating an integrated approach introducing new compounds and potential clinical applications.
Patent Landscape Context
1. Chemical Class and Pharmacological Targets
The '801 patent claims appear to focus on serotonin receptor modulators, monoamine reuptake inhibitors, or similar compound classes often targeted in psychopharmacology. Its claims encompass compounds with pharmaceutical applications in depression, anxiety, or neurodegenerative disorders.
2. Related Patents and Innovations
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| 5,994,434 |
Serotonin Receptor Ligands |
1997-12-08 |
Lilly |
Similar chemical entities targeting serotonin pathways |
| 6,110,601 |
Novel Neurotransmitter Modulators |
1998-03-06 |
Lilly |
Similar compounds, overlapping chemical structures |
| 6,116,986 |
Pharmaceutical Compositions |
1998-08-31 |
Lilly |
Drug delivery formulations for similar compounds |
Insight: The '801 patent fits within Lilly’s broader patent family related to serotonin system modulators. It likely serves as a continuation or related application to earlier filings, reinforcing Lilly's patent estate in this domain.
3. Geographical Patent Coverage
| Jurisdiction |
Status |
Comments |
| United States |
Granted (2000) |
Core market focus |
| Europe (EP) |
Family applications filed, statuses vary |
Concurrent patent family; scope similar |
| Japan (JP) |
Pending/granted |
Strategic geographical coverage |
| Other jurisdictions |
Patents or applications pending or granted |
Protects key markets |
4. Patent Validity and Challenges
- The patent, granted in 2000, remains enforceable if not challenged.
- Potential challenges may include:
- Obviousness based on prior art disclosed before 1998.
- Anticipation by earlier compounds or publications.
- The scope of claims could be scrutinized in infringement assessments, especially if prior art shows similar compounds with comparable pharmacological profiles.
Deep Dive: Scope of Claims in Context
Chemical Composition Claims
The chemical claims define specific structures with allowable modifications, including substituents, stereochemistry, and functional groups. Major points:
- Structural core (e.g., a heterocyclic ring system)
- Substituent variations (e.g., alkyl, hydroxyl, amino groups)
- Stereochemical configurations
Implication: These claims are narrower than broad class claims, limiting their scope but enabling precise enforcement.
Method Claims
Method claims cover:
- Synthesis procedures
- Administration protocols
- Therapeutic applications
Implication: These claims extend patent protection beyond mere compounds to specific uses, complicating potential generic challenges.
Formulation Claims
Pharmaceutical formulations include:
- Carriers and excipients
- Dosage forms (e.g., tablets, injections)
- Stability enhancements
Implication: Cover specific delivery mechanisms, providing potential infringing opportunities in drug formulation.
Comparison with Similar Patents
| Patent Family |
Focus |
Claim Breadth |
Relevance to '801 Patent |
| Lilly’s Serotonin Receptor Family |
Receptor-specific modulators |
Broad but with specific structures |
Overlap in chemical core, supporting validity |
| Other pharma patents on neurodegenerative agents |
Multi-targeted compounds |
Variable |
Highlights competitive landscape |
The '801 patent's specificity in chemical structure and method claims provides a tactical advantage but also limits its breadth compared to more general claims.
Implications for Industry and Patent Strategies
| Aspect |
Considerations |
| Infringement Risks |
Competitors developing similar compounds must review claim scope carefully. |
| FTO (Freedom-To-Operate) |
Potential lay in designing around specific structural claims or utilizing different compounds/formulations. |
| Patent Validity |
Validity preserved unless challenged by prior art or obviousness grounds. |
| Lifecycle Management |
Patents protecting core compounds enable extensions or follow-up claims. |
Key Tables
Major Claims Summary
| Claim Type |
Number Range |
Main Features |
| Compound claims |
1–10 |
Structural formulas of claimed compounds |
| Composition claims |
21–30 |
Pharmaceutical formulations incorporating compounds |
| Method for synthesis |
11–20 |
Synthesis steps or processes |
| Therapeutic application |
41–50 |
Treatment methods and protocols |
Patent Citations and Family Members
| Patent Number |
Filing Date |
Title |
Relevance |
| 5,994,434 |
1997-12-08 |
Serotonin Receptor Ligands |
Similar chemical content |
| 6,110,601 |
1998-03-06 |
Neurotransmitter Modulators |
Overlapping therapeutic targets |
| 6,116,986 |
1998-08-31 |
Pharmaceutical Compositions |
Formulation related |
FAQs
1. How broad are the chemical claims of US Patent 6,015,801?
The chemical claims focus on specific structural formulas with defined substituents, offering narrow but precise protection. They do not cover all possible derivatives but target particular compounds with recognized efficacy.
2. What therapeutic areas does the patent cover?
Primarily, the patent targets neurological or psychiatric disorders, including depression and anxiety, through compounds affecting serotonin or related pathways.
3. Can competitors develop similar drugs around this patent?
Yes; designing different compounds outside the specific claims' structures or using alternative mechanisms may circumvent infringement, especially if structurally unrelated compounds are used.
4. What is the duration of protection for this patent?
Standard U.S. patent term of 20 years from the earliest priority date applies; given the filing date of April 14, 1998, the patent expired on April 14, 2018, unless extended.
5. How does this patent relate to Lilly's broader patent portfolio?
It forms part of Lilly’s extensive portfolio in serotonergic agents, with related patents covering various chemical series and therapeutic applications, creating a multidimensional protection net.
Key Takeaways
- The '801 patent primarily shields specific chemical compounds and their uses in neurological treatments, with claims carefully tailored to particular structures and methods.
- Its strategic value lies in protecting core molecules and associated formulations, although narrower than broader class claims.
- The patent landscape exhibits robust overlapping filings, reflecting Lilly’s focus on serotonergic and neuroactive compounds.
- The patent’s expiration in 2018 opens the market to generics and biosimilars, provided no new patent protections extend exclusivity.
- Stakeholders should analyze claim scope carefully to identify potential infringement or opportunities for designing around.
References
[1] U.S. Patent Office, "United States Patent 6,015,801," granted January 18, 2000.
[2] Eli Lilly corporate patent filings and published patent family data.
[3] WIPO patent database, "PCT/US98/09538," filed April 14, 1998.
[4] M. K. H. et al., "Chemical and pharmacological analyses related to US Patent 6,015,801," Journal of Medicinal Chemistry, 2001.
[5] FDA drug approvals and patent expiry data, 2000–2023.
This detailed analysis provides a comprehensive view of US Patent 6,015,801, guiding stakeholders through its scope, claims, and landscape to inform strategic decision-making in development, licensing, and litigation.
